Improved Pharma announces new collaboration

Improved Pharma is pleased to announce the addition of Ruba Alajlouni to the team. Ruba brings expertise in regulatory and quality compliance along with hands-on experience in microbiology, cell culture, molecular biology, protein purification, Raman spectroscopy and chemometrics. She started independent consulting work right after getting her second MS degree from Stephen Byrn’s lab Read more

Improved Pharma announces new collaboration2021-08-20T13:23:16+00:00

Additional Research on Bedaquiline Salts recently published in Acta Crystallographica

Improved Pharma is pleased to announce an additional open-source publication describing the structures of Bedaquiline maleate salts that is now available to download.  Previously, our lab was able to identify promising new benzoate salts of Bedaquiline, a first-in-class drug used in the treatment of tuberculosis.  This current publication describes the successfully solved crystal structures obtained from Read more

Additional Research on Bedaquiline Salts recently published in Acta Crystallographica2021-05-03T12:59:14+00:00

Improved Pharma has Expanded their Laboratory Space to Support the Growing Business

WEST LAFAYETTE, IND. (PRWEB) APRIL 26, 2021 Improved Pharma is delighted to announce the expansion of its current laboratory to accommodate additional research capabilities. The addition of the newly acquired laboratory facility in the Purdue Kurz Technology Center has effectively doubled the previous laboratory space and will allow for the acquisition of new instrumentation in Read more

Improved Pharma has Expanded their Laboratory Space to Support the Growing Business2021-04-26T12:13:21+00:00

Improved Pharma announces recent publication on expediting preclinical formulation development of amorphous lapatinib using mini-tab formulations in pediatrics

Dr, Stephen Byrn, CSO of Improved Pharma, was a key contributor to a recent publication describing the usefulness of mini-tablets in monitoring the dose-response of lapatinib solid amorphous dispersions in juvenile pigs.   Juvenile pigs have been well-established as an effective pediatric model.  The use of mini-tabs allowed for dose flexibility as the the amount of tablets dosed could Read more

Improved Pharma announces recent publication on expediting preclinical formulation development of amorphous lapatinib using mini-tab formulations in pediatrics2021-04-19T12:26:44+00:00

Improved Pharma announces new publication on amorphous dispersions

A recent collaboration with our colleagues further advances the field of X-ray pair distribution function analysis applied to the analysis of amorphous solid dispersions. In this paper, we present the results of different polymer:flubendazole drug dispersions exposed to aging conditions. We discovered that if the polymer has ion-base interactions with the drug, the resulting Read more

Improved Pharma announces new publication on amorphous dispersions2021-04-12T15:10:54+00:00

Control of Nitrosamine Impurities in Human Drugs

In February 2021, the FDA issued a guidance aimed at preventing unacceptable levels of nitrosamine impurities in pharmaceutical products.  This guidance required a risk assessment to be completed by March 31, 2021.  This is because nitrosamines are genotoxic and are classified as possible or probable carcinogens. The guidance also described conditions under which nitrosamines can Read more

Control of Nitrosamine Impurities in Human Drugs2021-03-12T22:14:19+00:00

Recent research on bedaquiline selected for the November cover of Acta Crystallographic

Improved Pharma is pleased to announce the open-source publication of research into finding new salts of bedaquiline, an important drug for the treatment of tuberculosis. The drug is currently marketed in the US as the fumarate salt. Our team discovered several new salts, and the crystal structures of two benzoate salts are described in this Read more

Recent research on bedaquiline selected for the November cover of Acta Crystallographic2020-12-14T13:52:51+00:00

Improved Pharma presenting at AAPS 2020 PHARMSCI 360 with Rapid Fire Presentation and Poster

WEST LAFAYETTE, IND. (PRWEB) OCTOBER 26, 2020 Interact with us via poster number 924440 and the Advances and Innovation in Formulation Development Rapid Fire session. On Wednesday October 28th, Dr. Pamela Smith, COO of Improved Pharma, will present “Synchrotron-Based Formulation Development” in the Rapid Fire: Formulation and Quality – Chemical session. Those registered for the meeting Read more

Improved Pharma presenting at AAPS 2020 PHARMSCI 360 with Rapid Fire Presentation and Poster2020-10-26T17:34:00+00:00

Published book chapter on Solid-State Characterization

Improved Pharma COO Pamela Smith is co-author of a chapter in the latest edition of Specification of Drug Substances and Products: Development and Validation of Analytical Methods. The chapter, Solid-State Characterization – Method Development and Validation, focuses on the key issues that must be addressed when developing solid-state methods. Method development and validation for pharmaceuticals is Read more

Published book chapter on Solid-State Characterization2020-10-21T15:04:46+00:00

Excipient Effects on Drug Product Performance

Traditionally, excipients utilized for the development of pharmaceutically-marketed drug products have been considered largely inert. Excipients are added to formulations for a variety of reasons that may include assisting processability of the drug product formulation, controlling the disintegration rate to facilitate regional dissolution along the gastrointestinal tract (GIT), bulking up the dosage form to enable Read more

Excipient Effects on Drug Product Performance2020-09-21T19:19:30+00:00
Go to Top